Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 22, 2018
Pharmacy Choice - News - Drug Delivery Systems - February 22, 2018

Pharmacy News

 Drug Delivery Systems
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 111     Next >>     Go To Page:

2/21/18 - CTT Pharmaceutical Holdings, Inc., (CTTH) Announces Canadian Patent for Orally Administrable Nanonized Cannabinoids, Opioids and Other Pharmaceutical Agents
CTT Pharmaceutical Holdings, Inc.,, an innovative life sciences company with an extensive portfolio of IP in novel drug delivery systems, is pleased to announce that the Canadian Intellectual Property Office has granted Canadian Patent# 2,922,959, titled, Orally Administrable Composition, to the Company. Pankaj Modi, CEO of CTTH. The cla
2/21/18 - CURE Pharmaceutical Adds Healthcare Luminary To Advisory Board, Secures $1 Million Investment as a Bridge to Uplisting
CURE Pharmaceutical, an innovative drug delivery and development company, today announced Gene Salkind, M.D. joined the company s Advisory Board and also became the first investor of larger financing that will lead CURE to an application with the national securities exchange within the first quarter. The fact that we have the time and finan
2/21/18 - Electric Nasal Spray Market Driven by the Technological Advancement and Demand of Improvement in Medical Science: An electronic system is introduced in the electric nasal spray market which identifies the type of drug and also checks its expiry date.
Albany, NY 02/21/2018 Effective delivery of drugs is one of the issue for which many researches are conducted all over the world. Various developments are introduced continuously for this purpose. Nasal spray is now getting popular in the world as a more effective method of drug delivery.
2/21/18 - Eyenovia Advances MicroPine for Myopia into Phase III Clinical Development and Appoints Stanford Professor Dr. Douglas Fredrick to its Scientific Advisory Board and Myopia Program Steering Committee
Eyenovia Inc.,, a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that following discussions with the U.S. Food and Drug Administration, it has received clear feedback on its pivotal trial...
2/21/18 - Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors
SAN DIEGO- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the first subject has been treated in the DIMENSION study of FATE- NK100 for the treatment of advanced solid tumors. The clinical trial is intended t
2/21/18 - Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors [Sport360]
-Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the first subject has been treated in the DIMENSION study of FATE- NK100 for the treatment of advanced solid tumors. The clinical trial is intended to evaluate
2/21/18 - FDA Approves Osmotica Pharmaceutical's Once-Daily OSMOLEX ER extended-release tablets
Bridgewater- Osmotica Pharmaceutical US LLC, a privately-held specialty pharmaceutical company developing novel central nervous system treatments utilizing its proprietary osmotic drug delivery platform, announced today that the U.S. Food and Drug Administration has approved OSMOLEX ER, an amantadine extended release tablet, for the treatment of...
2/21/18 - Findings from AO Research Institute Provides New Data about Drug Delivery Systems (Drug delivery systems functionalized with bone mineral seeking...
Findings from AO Research Institute Provides New Data about Drug Delivery Systems. According to news reporting from Davos, Switzerland, by NewsRx journalists, research stated, "The systemic administration of drugs to treat bone diseases is often associated with poor uptake of the drug in the targeted tissue, potential systemic toxicity and suboptim
2/21/18 - G1 THERAPEUTICS, INC. - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere in this Annual Report. This discussion contains forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives,...
2/21/18 - Global Investors Back Rani Therapeutics With $53 Million As Company Moves To Clinical Trials
By a News Reporter-Staff News Editor at Biotech Week Rani Therapeutics, the developer of a pill designed to replace injectable drug delivery for patients suffering from chronic diseases, announced that it has raised $53 million to invest in manufacturing in preparation for human clinical trials. New investors include GeneScience Pharmaceuticals,
2/21/18 - Insmed Extends ALIS Intellectual Property Protection to 2035 with Issuance of Ninth U.S. Patent [HotelierMiddleEast.com]
-Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the United States Patent and Trademark Office issued U.S. Patent Number 9,895,385 concerning methods for treating nontuberculous mycobacterial lung infections, including NTM lung infections caused by Mycobacterium
2/21/18 - La Jolla Pharmaceutical Company Announces the Treatment of First Patient in GIAPREZA? (angiotensin II) Pediatric Study
La Jolla Pharmaceutical Company today announced that the first pediatric patient has been treated in LJ501-CRH02, La Jolla s open-label study of GIAPREZA TM, injection for intravenous infusion, in pediatric patients with shock who remain hypotensive despite receiving fluid and current standard-of-care vasopressor therapy.. LJ501-CRH02 is an...
2/21/18 - Mylan Receives Tentative Approval for Combination HIV Treatment DTG FTC TAF under FDA's PEPFAR Program
HERTFORDSHIRE, England and PITTSBURGH- Global pharmaceutical company Mylan N.V. today announced receipt of tentative approval from the U.S. Food and Drug Administration under the U.S. President's Emergency Plan for AIDS Relief for its New Drug Application for Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg.
2/21/18 - National Comprehensive Cancer Network adds Jazz Pharmaceuticals' Vyxeos? daunorubicin and cytarabine Liposome for Injection to Clinical Practice...
National Comprehensive Cancer Network adds Jazz Pharmaceuticals' Vyxeos? daunorubicin and cytarabine Liposome for Injection to Clinical Practice Guidelines in Oncology. By a News Reporter-Staff News Editor at Biotech Week Jazz Pharmaceuticals plc announced that the National Comprehensive Cancer Network added Vyxeos? liposome for injecti
2/21/18 - Neos Therapeutics Reiterates Confidence in Strategic Plan and Value Creation Opportunities
DALLAS and FORT WORTH- Neos Therapeutics, Inc., a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release products using its proprietary modified-release drug delivery and orally disintegrating tablet technologies, issued the following statement in response to the announcement from PDL...
2/21/18 - Patent Issued for Method and Apparatus for Recognition of Inhaler Actuation (USPTO 9883786)
By a News Reporter-Staff News Editor at Biotech Week From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Hanina, Adam; Kessler, Gordon; Guan, Lei; Lai, Dehua, filed on November 12, 2012, was published online on February 6, 2018. The patent's assignee for patent number 9883786 is AIC Innovations Group Inc.. News edi
2/21/18 - Research Conducted at Technical University of Denmark Has Provided New Information about Drug Delivery Systems (On the use of liposome controls in...
Our news journalists obtained a quote from the research from the Technical University of Denmark, "Many characteristics of these EV-based drug delivery vehicles suggest them to be superior at residing in the systemic circulation and possibly at mediating therapeutic effects compared to synthetic drug delivery vehicles, e.g. liposomes.
2/21/18 - Researchers at University of Regensburg Target Drug Delivery Systems (Preventing Obstructions of Nanosized Drug Delivery Systems by the Extracellular...
Researchers at University of Regensburg Target Drug Delivery Systems. According to news reporting from Regensburg, Germany, by NewsRx journalists, research stated, "Although nanosized drug delivery systems are promising tools for the treatment of severe diseases, the extracellular matrix constitutes a major obstacle that endangers therapeutic succe
2/21/18 - Researchers from Federal University Report New Studies and Findings in the Area of Drug Delivery Systems (Effect on adhesion of a nanocapsules-loaded...
By a News Reporter-Staff News Editor at Biotech Week Investigators discuss new findings in Drugs and Therapies- Drug Delivery Systems. According to news originating from Porto Alegre, Brazil, by NewsRx correspondents, research stated, "This study aimed to evaluate the in situ degree of conversion, contact angle, and immediate and long-term bond s
2/21/18 - Researchers from Jilin Normal University Detail New Studies and Findings in the Area of Drug Delivery Systems (Multifunctional zinc-based hollow...
According to news originating from Changchun, People's Republic of China, by NewsRx correspondents, research stated, "Novel multifunctional ZnO@ nanocomposites as a pH-responsive drug delivery system were designed and successfully synthesized by a self-assembling method. Funders for this research include National Programs for High Technology...
2/21/18 - Skinvisible, Inc. (SKVI) Aims to Increase Shareholder Value through Proposed Deal with Quoin
Drug delivery platform ideal for M&A-driven growth $80 billion global dermatology market $30 billion global over-the-counter skincare market Half of the 100 million surgeries performed in the U.S. require post-surgical pain medication, according to Transparency Market Research report. If history repeats itself, as we are often told, then Skinvisibl
2/21/18 - Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial Results on February 27 2018
DUBLIN- Theravance Biopharma, Inc. today announced that it will release financial results for the period ended December 31, 2017 after market close on Tuesday, February 27, 2018. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investor..
2/21/18 - Transdermal Drug Delivery Research Report 2018 - Technologies, Markets, and Companies - ResearchAndMarkets.com
By a News Reporter-Staff News Editor at Biotech Week The "Transdermal Drug Delivery- Technologies, Markets, and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com' s offering. This report deals with transdermal drug delivery- an approach used to deliver drugs through the skin for therapeutic use as an alternative t
2/21/18 - UNITED THERAPEUTICS CORP - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
We currently market and sell the following commercial products: ? Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil, approved by the FDA for subcutaneous and intravenous administration to diminish symptoms associated with exercise in PAH patients. Remodulin has also been approved in various countries...
2/21/18 - UPDATECTT Pharmaceutical Holdings, Inc., (CTTH) Announces Canadian Patent for Orally Administrable Nanonized Cannabinoids, Opioids and Other Pharmaceutical Agents
CTT Pharmaceutical Holdings, Inc.,, an innovative life sciences company with an extensive portfolio of IP in novel drug delivery systems, is pleased to announce that the Canadian Intellectual Property Office has granted Canadian Patent# 2,922,959, titled, Orally Administrable Composition, to the Company. Pankaj Modi, CEO of CTTH. The cla
Articles(s): 1 - 25 of 111     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415